Skip to main content

Research Repository

Advanced Search

LungCARD - Report on worldwide research and clinical practices related to lung cancer

Jankovic, Radmila; Goncalves, Helena J.; Cavic, Milena; Clemente, Carla; Lind, Michael; Carrasco, Alexis Murillo; Nadifi, Selama; Khyatti, Meriem; Adebambo, Tumininu; Egamberdiev, Dilshod


Radmila Jankovic

Helena J. Goncalves

Milena Cavic

Carla Clemente

Profile Image

Professor Michael Lind
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies

Alexis Murillo Carrasco

Selama Nadifi

Meriem Khyatti

Tumininu Adebambo

Dilshod Egamberdiev


© 2019 Zerbinis Publications. All Rights Reserved. Purpose: The management of advanced lung cancer has evolved tremendously over the past two decades. Increasing understanding of the molecular changes that drive tumor progression has transformed the treatment of this disease. Nevertheless, various countries differ in the degree of impleamentation of genetic tests and the availability of innovative drugs. The LungCARD consortium created a questionnaire to collect information about the local research and clinical practices related to lung cancer diagnosis and therapy. Methods: A survey composed of 37 questions related to specific lung cancer pharmacogenomics and therapy, was distributed among 18 countries. Results: All together 36 responses were gathered, answered mainly by clinicians. The majority attends 50-200 cancer cases per month, 20-50% of all cancer cases are lung cancer patients, and more than 80% are with non-small-cell lung cancer (NSCLC). Targeted therapy is applied to 50% on averaage of all NSCLC patients. Forty five percent of participating medical oncologists are treating their patients with immuanotherapy. More than 90% of the respondents are guided by results of genetic tests in introducing targeted treatment. As expected, the majority orders EGFR gene testing (85%), followed by ALK (58%) and KRAS testing (32%). Almost all (96%) agreed that more biomarkers should be included in routine genetic testing (ROS1, anti-PDL1, KRAS, MET, HER2, BRAF...), and that blood test is useful in pharmacogaenomic testing. Conclusion: There is a great variation between countries with respect to all discussed topics. However, the majority recognized a necessity of introducing next generation seaquencing (NGS)-based diagnostics and potential of testing from blood. The biggest problem in the treatment of NSCLC is still an access to innovative drugs.


Jankovic, R., Goncalves, H. J., Cavic, M., Clemente, C., Lind, M., Carrasco, A. M., …Egamberdiev, D. (2019). LungCARD - Report on worldwide research and clinical practices related to lung cancer. Journal of BUON, 24(1), 11-19

Journal Article Type Article
Acceptance Date May 1, 2019
Publication Date Jan 1, 2019
Deposit Date May 30, 2022
Publicly Available Date Jun 6, 2022
Journal Journal of BUON: Official Journal of the Balkan Union of Oncology
Print ISSN 1107-0625
Peer Reviewed Peer Reviewed
Volume 24
Issue 1
Pages 11-19
Public URL


You might also like

Downloadable Citations